In the rapidly growing and innovative therapeutic area, how do clinical trial sponsors effectively navigate the multitude of unique intricacies involved in cell and gene therapy development?
In a recent joint thought leadership article for PharmaPhorum, IQVIA experts Patrick Brady and Diego Correa and IQVIA Laboratories' Alan Wookey discuss several noteworthy considerations that impact complex Cell and Gene Therapy (CAGT) development. This can include the coordination and oversight of end-to-end laboratory assessments and evolving regulatory guidance in a fast-paced landscape.
These experts' collective insights emphasize the importance of accounting for the wide-ranging spectrum of needs for CAGT development and accordingly mapping out key decisions early in the trial planning process
Related Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Biorepository and Specimen Management
Your biological specimens are irreplaceable assets – trust them with a proven partner
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
Helping you master your lab data
Improved oversight with your lab data now in full view
NASH and Liver Disease Capabilities
Nonalcoholic Fatty Liver Diseases & Non-alcoholic Steatohepatitis (NAFLD & NASH)
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Pediatric Initiative
Optimizing small blood volumes to prevent canceled tests in clinical trials for pediatric patients
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
